Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes
- 22 June 2010
- journal article
- review article
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 55 (25), 2878-2886
- https://doi.org/10.1016/j.jacc.2010.04.003
Abstract
No abstract availableThis publication has 35 references indexed in Scilit:
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trialsThe Lancet, 2009
- Aspirin for the Prevention of Cardiovascular Disease: U.S. Preventive Services Task Force Recommendation StatementAnnals of Internal Medicine, 2009
- Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Patients With Type 2 DiabetesA Randomized Controlled TrialJAMA, 2008
- The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial diseaseBMJ, 2008
- Platelet hyperactivity in type 2 diabetes: role of antiplatelet agentsDiabetes and Vascular Disease Research, 2008
- Primary Prevention of Cardiovascular Diseases in People With Diabetes MellitusDiabetes Care, 2007
- Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?JCI Insight, 2003
- Unstable AnginaCirculation, 1995
- Final Report on the Aspirin Component of the Ongoing Physicians' Health StudyNew England Journal of Medicine, 1989
- Randomised trial of prophylactic daily aspirin in British male doctorsBMJ, 1988